PEOPLE ON THE MOVE
Ablynx
Former FDA immunologist Robert Zeldin has joined Ablynx as chief medical officer.
He previously worked in senior clinical development positions at Merck & CO. and Novartis, specialising in immunology, respiratory, dermatology and cardiovascular disease.
Before joining the pharmaceutical industry, Zeldin practiced as a doctor and was a medical officer at the FDA's Center for Biologics Evaluation and Research.
Welcoming the new recruit, Edwin Moses, CEO of Ablynx, said:"We are very pleased that someone with Robert's track record and experience is joining Ablynx as Chief Medical Officer. Partly based in the USA, he will be invaluable in supporting our global clinical development activities as well as our interactions with the regulatory agencies and other key stakeholders.
“His extensive industry experience, including his contribution in obtaining regulatory approval of innovative immunotherapies, will be very important in supporting Ablynx in the development of Nanobody-based therapeutics to address areas of high unmet need."
Ablynx has patented Nanobodies, therapeutic proteins based on single-domain antibody fragments, which it says “combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs.” The Belgium-based company has collaborations with AbbVie, Boehringer Ingelheim, Genzyme, Merck & Co., and others.
